08:01 AM EDT, 10/27/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday that long-term extensions of its phase 3 studies showed that its drug, Tremfya, maintained high rates of clinical and endoscopic remission in adults with moderately to severely active Crohn's disease through two years.

The drugmaker said the studies evaluated patients who received either subcutaneous or intravenous induction, followed by subcutaneous maintenance doses, comparing Tremfya to placebo, and in one study, to Stelara.

Safety data from the long-term extension periods of the studies were consistent with the well-established safety profile of Tremfya, the company said.